Oramed Pharmaceuticals
ORMP
103 hedge funds and large institutions have $78.4M invested in Oramed Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 24 closing their positions.
157% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $928K
21% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 28
1.12% more ownership
Funds ownership: 22.52% → 23.64% (+1.1%)
11% less funds holding
Funds holding: 116 → 103 (-13)
36% less capital invested
Capital invested by funds: $122M → $78.4M (-$43.8M)
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$4.45M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.95M |
| 3 |
BlackRock
New York
|
+$2.78M |
| 4 |
Morgan Stanley
New York
|
+$2.12M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.57M |
| 3 |
Renaissance Technologies
New York
|
-$2.9M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.65M |
| 5 |
HF
HRT Financial
New York
|
-$916K |
ORMP Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2022, worth a combined $78.4M — down 36% from $122M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ORMP and 12 opened new positions — a net loss of 12 holders — while 28 trimmed existing stakes and 34 added.
The largest buyer was Two Sigma Advisers, adding an estimated $4.45M. The largest seller was Millennium Management, cutting an estimated $4.08M.
- 103 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2022, down from 116 in Q4 2021.
- Funds reported $78.4M of Oramed Pharmaceuticals stock for Q1 2022, down 36% quarter-over-quarter.
- 12 funds opened new Oramed Pharmaceuticals positions in Q1 2022 and 24 closed out, a net change of -12 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2022 was Two Sigma Advisers, an estimated $4.45M added.
- The largest Oramed Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $4.08M sold.
Based on aggregated 13F filings for Q1 2022.